Literature DB >> 19067761

Germline polymorphism of cancer susceptibility genes in gynecologic cancer.

Masatsugu Ueda1, Eisaku Toji, Osamu Nunobiki, Shinji Izuma, Yoshiaki Okamoto, Kiyo Torii, Sadamu Noda.   

Abstract

The multifactorial process of carcinogenesis involves mutations in oncogenes, or tumor suppressor genes, as well as the influence of environmental etiological factors. Common DNA polymorphisms in low penetrance genes have emerged as genetic factors that seem to modulate an individual's susceptibility to malignancy. Genetic studies, which lead to a true association, are expected to increase understanding of the pathogenesis of each malignancy and to be a powerful tool for prevention and prognosis in the future. Here, we review the findings of genetic association studies of gene polymorphisms in gynecologic cancer with special reference to glutathione-S-transferase, FAS/CD95 and p53 genes including our recent research results.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19067761     DOI: 10.1111/j.1749-0774.2008.00058.x

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.374


  80 in total

1.  Codon 72 polymorphism of p53 and its association with cervical cancer.

Authors:  I Zehbe; G Voglino; E Wilander; F Genta; M Tommasino
Journal:  Lancet       Date:  1999-07-17       Impact factor: 79.321

Review 2.  Regulation of p53 function.

Authors:  D B Woods; K H Vousden
Journal:  Exp Cell Res       Date:  2001-03-10       Impact factor: 3.905

Review 3.  Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility.

Authors:  T R Rebbeck
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1997-09       Impact factor: 4.254

4.  Cervical cancer cells induce apoptosis of cytotoxic T lymphocytes.

Authors:  D N Contreras; P H Krammer; R K Potkul; P Bu; J L Rossi; A M Kaufmann; L Gissmann; L Qiao
Journal:  J Immunother       Date:  2000-01       Impact factor: 4.456

5.  Glutathione-S-transferase and p53 polymorphisms in cervical carcinogenesis.

Authors:  Masatsugu Ueda; Yao-Ching Hung; Yoshito Terai; Junko Saito; Osamu Nunobiki; Sadamu Noda; Minoru Ueki
Journal:  Gynecol Oncol       Date:  2005-03       Impact factor: 5.482

6.  Glutathione-S-transferase polymorphisms and risk of squamous-cell carcinoma of the head and neck.

Authors:  L Cheng; E M Sturgis; S A Eicher; D Char; M R Spitz; Q Wei
Journal:  Int J Cancer       Date:  1999-06-21       Impact factor: 7.396

7.  P53 codon 72 polymorphism and BRCA 1 and 2 mutations in ovarian epithelial malignancies in black South Africans.

Authors:  R J Pegoraro; M Moodley; L Rom; R Chetty; J Moodley
Journal:  Int J Gynecol Cancer       Date:  2003 Jul-Aug       Impact factor: 3.437

Review 8.  Glutathione-associated enzymes in anticancer drug resistance.

Authors:  K D Tew
Journal:  Cancer Res       Date:  1994-08-15       Impact factor: 12.701

9.  p53 codon 72 polymorphism and risk of cervical cancer in UK.

Authors:  A N Rosenthal; A Ryan; R M Al-Jehani; A Storey; C A Harwood; I J Jacobs
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

10.  Human glutathione S-transferase deficiency as a marker of susceptibility to epoxide-induced cytogenetic damage.

Authors:  J K Wiencke; K T Kelsey; R A Lamela; W A Toscano
Journal:  Cancer Res       Date:  1990-03-01       Impact factor: 12.701

View more
  10 in total

1.  Association between FAS A670G polymorphism and susceptibility to cervical cancer: evidence from a meta-analysis.

Authors:  Jian Shen; Ning-Xia Sun
Journal:  Tumour Biol       Date:  2013-07-31

2.  CD95 rs1800682 polymorphism and cervical cancer risk: evidence from a meta-analysis.

Authors:  Yan Zhang; Shengchun Tong; Lihua Guan; Fei Na; Wei Zhao; Li Wei
Journal:  Tumour Biol       Date:  2013-10-11

3.  Clinical significance of hWAPL polymorphisms in the risk of cervical carcinogenesis.

Authors:  Osamu Nunobiki; Daisuke Sano; Sakae Hata; Toshitada Ogasawara; Masatsugu Ueda
Journal:  Hum Cell       Date:  2018-01-23       Impact factor: 4.174

4.  GSTM1, GSTT1, and NQO1 polymorphisms in cervical carcinogenesis.

Authors:  Osamu Nunobiki; Masatsugu Ueda; Hikari Akise; Shinji Izuma; Kiyo Torii; Yoshiaki Okamoto; Ichiro Tanaka; Sadamu Noda; Kyoko Akashi; Taro Higashida
Journal:  Hum Cell       Date:  2015-02-20       Impact factor: 4.174

5.  Potential impact of (rs 4645878) BAX promoter -248G>A and (rs 1042522) TP53 72Arg>pro polymorphisms on epithelial ovarian cancer patients.

Authors:  S Dholariya; R Mir; M Zuberi; P Yadav; G Gandhi; N Khurana; A Saxena; P C Ray
Journal:  Clin Transl Oncol       Date:  2015-07-25       Impact factor: 3.405

6.  Polymorphisms of p53 codon 72 and MDM2 promoter 309 and the risk of endometrial cancer.

Authors:  Osamu Nunobiki; Masatsugu Ueda; Michiko Yamamoto; Eisaku Toji; Naomi Sato; Shinji Izuma; Yoshiaki Okamoto; Kiyo Torii; Sadamu Noda
Journal:  Hum Cell       Date:  2009-11       Impact factor: 4.174

7.  Murine double-minute 2 homolog single nucleotide polymorphism 309 and the risk of gynecologic cancer.

Authors:  Masatsugu Ueda; Michiko Yamamoto; Osamu Nunobiki; Eisaku Toji; Naomi Sato; Shinji Izuma; Yoshiaki Okamoto; Kiyo Torii; Sadamu Noda
Journal:  Hum Cell       Date:  2009-05       Impact factor: 4.174

8.  Null genotypes of GSTM1 and GSTT1 contribute to risk of cervical neoplasia: an evidence-based meta-analysis.

Authors:  Lin-Bo Gao; Xin-Min Pan; Li-Juan Li; Wei-Bo Liang; Peng Bai; Li Rao; Xiao-Wei Su; Tao Wang; Bin Zhou; Yong-Gang Wei; Lin Zhang
Journal:  PLoS One       Date:  2011-05-23       Impact factor: 3.240

9.  Glutathione S-transferase polymorphism interactions with smoking status and HPV infection in cervical cancer risk: an evidence-based meta-analysis.

Authors:  Shuai Zhen; Chen-Ming Hu; Li-Hong Bian
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

Review 10.  XRCC1 and OGG1 Gene Polymorphisms and Breast Cancer: A Systematic Review of Literature.

Authors:  Ali Sanjari Moghaddam; Milad Nazarzadeh; Rezvan Noroozi; Hossein Darvish; Alireza Mosavi Jarrahi
Journal:  Iran J Cancer Prev       Date:  2016-02-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.